Haw Par's Share Price Appears to Undervalue Its Underlying Business -- Market Talk

Like
Comment
Favorite

Haw Par's Share Price Appears to Undervalue Its Underlying Business -- Market Talk

Dow Jones03-20 13:56

0556 GMT - Haw Par's share price seems to undervalue the cash generation of its underlying business, say Macquarie Capital analysts in a note. Haw Par, which owns pain relief brand Tiger Balm, has relatively stable healthcare sales and the analysts expect the company's 2026-2028 profit at S$276 million-S$292 million, excluding fair-value gains on investments. Haw Par also has holdings in United Overseas Bank and property developer UOL Group, both with strong market positions, they note. These investments represent around 70% of Macquarie's estimated net asset value for Haw Par, they say. A re-rating of Haw Par's underlying asset base could be a key share-price catalyst, they add. Macquarie starts coverage of Haw Par with an outperform rating and S$20.60 target price. Shares rise 2.6% to S$15.79. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

March 20, 2026 01:56 ET (05:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2620073492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 13:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620073492","market":"sh","top_or_hot":-1,"title":"Haw Par's Share Price Appears to Undervalue Its Underlying Business -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0556 GMT - <a href=\"https://laohu8.com/S/HAWPF\">Haw Par</a>'s share price seems to undervalue the cash generation of its underlying business, say <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> Capital analysts in a note. <a href=\"https://laohu8.com/S/HAWPY\">Haw Par</a>, which owns pain relief brand Tiger Balm, has relatively stable healthcare sales and the analysts expect the company's 2026-2028 profit at S$276 million-S$292 million, excluding fair-value gains on investments. Haw Par also has holdings in <a href=\"https://laohu8.com/S/UOVEF\">United Overseas</a> Bank and property developer UOL Group, both with strong market positions, they note. These investments represent around 70% of Macquarie's estimated net asset value for Haw Par, they say. A re-rating of Haw Par's underlying asset base could be a key share-price catalyst, they add. Macquarie starts coverage of Haw Par with an outperform rating and S$20.60 target price. Shares rise 2.6% to S$15.79. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2026 01:56 ET (05:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haw Par's Share Price Appears to Undervalue Its Underlying Business -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaw Par's Share Price Appears to Undervalue Its Underlying Business -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-20 13:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0556 GMT - <a href=\"https://laohu8.com/S/HAWPF\">Haw Par</a>'s share price seems to undervalue the cash generation of its underlying business, say <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> Capital analysts in a note. <a href=\"https://laohu8.com/S/HAWPY\">Haw Par</a>, which owns pain relief brand Tiger Balm, has relatively stable healthcare sales and the analysts expect the company's 2026-2028 profit at S$276 million-S$292 million, excluding fair-value gains on investments. Haw Par also has holdings in <a href=\"https://laohu8.com/S/UOVEF\">United Overseas</a> Bank and property developer UOL Group, both with strong market positions, they note. These investments represent around 70% of Macquarie's estimated net asset value for Haw Par, they say. A re-rating of Haw Par's underlying asset base could be a key share-price catalyst, they add. Macquarie starts coverage of Haw Par with an outperform rating and S$20.60 target price. Shares rise 2.6% to S$15.79. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2026 01:56 ET (05:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6506","symbol_name":"制药与医学研究概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620073492","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620073492","pubTimestamp":1773986160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0556 GMT - Haw Par's share price seems to undervalue the cash generation of its underlying business, say Macquarie Capital analysts in a note. Haw Par, which owns pain relief brand Tiger Balm, has relatively stable healthcare sales and the analysts expect the company's 2026-2028 profit at S$276 million-S$292 million, excluding fair-value gains on investments. Haw Par also has holdings in United Overseas Bank and property developer UOL Group, both with strong market positions, they note. These investments represent around 70% of Macquarie's estimated net asset value for Haw Par, they say. A re-rating of Haw Par's underlying asset base could be a key share-price catalyst, they add. Macquarie starts coverage of Haw Par with an outperform rating and S$20.60 target price. Shares rise 2.6% to S$15.79. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6506":"制药与医学研究概念","BK6079":"制药","IE0031814969.USD":"FSSA ASEAN ALL CAP FUND \"I\" (USD) ACC","H02.SI":"虎豹企业","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC"},"translate_title":"Haw Par的股价似乎低估了其基础业务——市场讨论","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"H02.SI":0.9},"content_text":"0556 GMT - Haw Par's share price seems to undervalue the cash generation of its underlying business, say Macquarie Capital analysts in a note. Haw Par, which owns pain relief brand Tiger Balm, has relatively stable healthcare sales and the analysts expect the company's 2026-2028 profit at S$276 million-S$292 million, excluding fair-value gains on investments. Haw Par also has holdings in United Overseas Bank and property developer UOL Group, both with strong market positions, they note. These investments represent around 70% of Macquarie's estimated net asset value for Haw Par, they say. A re-rating of Haw Par's underlying asset base could be a key share-price catalyst, they add. Macquarie starts coverage of Haw Par with an outperform rating and S$20.60 target price. Shares rise 2.6% to S$15.79. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2026 01:56 ET (05:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}